Sen. William Delgado
Filed: 4/23/2013
| |||||||
| |||||||
| |||||||
1 | AMENDMENT TO SENATE BILL 1454
| ||||||
2 | AMENDMENT NO. ______. Amend Senate Bill 1454, AS AMENDED, | ||||||
3 | by replacing everything after the enacting clause with the | ||||||
4 | following:
| ||||||
5 | "Section 5. The Wholesale Drug Distribution Licensing Act | ||||||
6 | is amended by changing Section 40 as follows:
| ||||||
7 | (225 ILCS 120/40) (from Ch. 111, par. 8301-40)
| ||||||
8 | (Section scheduled to be repealed on January 1, 2023)
| ||||||
9 | Sec. 40. Rules and regulations. The Department shall
make | ||||||
10 | any rules and regulations, not inconsistent with law, as may be
| ||||||
11 | necessary to carry out the purposes and enforce the provisions | ||||||
12 | of this Act.
Rules and regulations that incorporate and set | ||||||
13 | detailed standards for
meeting each of the license | ||||||
14 | prerequisites set forth in Section 25 of this
Act shall be | ||||||
15 | adopted no later than September 14, 1992.
All rules and | ||||||
16 | regulations promulgated under this Section shall
conform to |
| |||||||
| |||||||
1 | wholesale drug distributor licensing guidelines formally | ||||||
2 | adopted
by the FDA at 21 C.F.R. Part 205. In case of conflict | ||||||
3 | between any rule
or regulation adopted by the Department and | ||||||
4 | any FDA wholesale drug
distributor guideline, the FDA guideline | ||||||
5 | shall control.
| ||||||
6 | Notwithstanding any other provision of law, a distributor | ||||||
7 | licensed and regulated by the Department of Financial and | ||||||
8 | Professional Regulation, and registered and regulated by the | ||||||
9 | United States Drug Enforcement Administration, shall be exempt | ||||||
10 | from the storage, reporting, ordering, record keeping, and | ||||||
11 | physical security control requirements for Schedule II | ||||||
12 | controlled substances with regard to any material, compound, | ||||||
13 | mixture, or preparation containing Hydrocodone. These | ||||||
14 | Controlled Substances shall be subject to the same requirements | ||||||
15 | as those imposed for Schedule III controlled substances. | ||||||
16 | (Source: P.A. 87-594 .)
| ||||||
17 | Section 10. The Illinois Controlled Substances Act is | ||||||
18 | amended by changing Sections 102, 206, 208, 316, 319, and 320 | ||||||
19 | and by adding Section 317.5 as follows: | ||||||
20 | (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) | ||||||
21 | Sec. 102. Definitions. As used in this Act, unless the | ||||||
22 | context
otherwise requires:
| ||||||
23 | (a) "Addict" means any person who habitually uses any drug, | ||||||
24 | chemical,
substance or dangerous drug other than alcohol so as |
| |||||||
| |||||||
1 | to endanger the public
morals, health, safety or welfare or who | ||||||
2 | is so far addicted to the use of a
dangerous drug or controlled | ||||||
3 | substance other than alcohol as to have lost
the power of self | ||||||
4 | control with reference to his or her addiction.
| ||||||
5 | (b) "Administer" means the direct application of a | ||||||
6 | controlled
substance, whether by injection, inhalation, | ||||||
7 | ingestion, or any other
means, to the body of a patient, | ||||||
8 | research subject, or animal (as
defined by the Humane | ||||||
9 | Euthanasia in Animal Shelters Act) by:
| ||||||
10 | (1) a practitioner (or, in his or her presence, by his | ||||||
11 | or her authorized agent),
| ||||||
12 | (2) the patient or research subject pursuant to an | ||||||
13 | order, or
| ||||||
14 | (3) a euthanasia technician as defined by the Humane | ||||||
15 | Euthanasia in
Animal Shelters Act.
| ||||||
16 | (c) "Agent" means an authorized person who acts on behalf | ||||||
17 | of or at
the direction of a manufacturer, distributor, | ||||||
18 | dispenser, prescriber, or practitioner. It does not
include a | ||||||
19 | common or contract carrier, public warehouseman or employee of
| ||||||
20 | the carrier or warehouseman.
| ||||||
21 | (c-1) "Anabolic Steroids" means any drug or hormonal | ||||||
22 | substance,
chemically and pharmacologically related to | ||||||
23 | testosterone (other than
estrogens, progestins, | ||||||
24 | corticosteroids, and dehydroepiandrosterone),
and includes:
| ||||||
25 | (i) 3[beta],17-dihydroxy-5a-androstane, | ||||||
26 | (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, |
| |||||||
| |||||||
1 | (iii) 5[alpha]-androstan-3,17-dione, | ||||||
2 | (iv) 1-androstenediol (3[beta], | ||||||
3 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
4 | (v) 1-androstenediol (3[alpha], | ||||||
5 | 17[beta]-dihydroxy-5[alpha]-androst-1-ene), | ||||||
6 | (vi) 4-androstenediol | ||||||
7 | (3[beta],17[beta]-dihydroxy-androst-4-ene), | ||||||
8 | (vii) 5-androstenediol | ||||||
9 | (3[beta],17[beta]-dihydroxy-androst-5-ene), | ||||||
10 | (viii) 1-androstenedione | ||||||
11 | ([5alpha]-androst-1-en-3,17-dione), | ||||||
12 | (ix) 4-androstenedione | ||||||
13 | (androst-4-en-3,17-dione), | ||||||
14 | (x) 5-androstenedione | ||||||
15 | (androst-5-en-3,17-dione), | ||||||
16 | (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- | ||||||
17 | hydroxyandrost-4-en-3-one), | ||||||
18 | (xii) boldenone (17[beta]-hydroxyandrost- | ||||||
19 | 1,4,-diene-3-one), | ||||||
20 | (xiii) boldione (androsta-1,4- | ||||||
21 | diene-3,17-dione), | ||||||
22 | (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 | ||||||
23 | [beta]-hydroxyandrost-4-en-3-one), | ||||||
24 | (xv) clostebol (4-chloro-17[beta]- | ||||||
25 | hydroxyandrost-4-en-3-one), | ||||||
26 | (xvi) dehydrochloromethyltestosterone (4-chloro- |
| |||||||
| |||||||
1 | 17[beta]-hydroxy-17[alpha]-methyl- | ||||||
2 | androst-1,4-dien-3-one), | ||||||
3 | (xvii) desoxymethyltestosterone | ||||||
4 | (17[alpha]-methyl-5[alpha] | ||||||
5 | -androst-2-en-17[beta]-ol)(a.k.a., madol), | ||||||
6 | (xviii) [delta]1-dihydrotestosterone (a.k.a. | ||||||
7 | '1-testosterone') (17[beta]-hydroxy- | ||||||
8 | 5[alpha]-androst-1-en-3-one), | ||||||
9 | (xix) 4-dihydrotestosterone (17[beta]-hydroxy- | ||||||
10 | androstan-3-one), | ||||||
11 | (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- | ||||||
12 | 5[alpha]-androstan-3-one), | ||||||
13 | (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- | ||||||
14 | hydroxyestr-4-ene), | ||||||
15 | (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- | ||||||
16 | 1[beta],17[beta]-dihydroxyandrost-4-en-3-one), | ||||||
17 | (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], | ||||||
18 | 17[beta]-dihydroxyandrost-1,4-dien-3-one), | ||||||
19 | (xxiv) furazabol (17[alpha]-methyl-17[beta]- | ||||||
20 | hydroxyandrostano[2,3-c]-furazan), | ||||||
21 | (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) | ||||||
22 | (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- | ||||||
23 | androst-4-en-3-one), | ||||||
24 | (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- | ||||||
25 | dihydroxy-estr-4-en-3-one), | ||||||
26 | (xxviii) mestanolone (17[alpha]-methyl-17[beta]- |
| |||||||
| |||||||
1 | hydroxy-5-androstan-3-one), | ||||||
2 | (xxix) mesterolone (1amethyl-17[beta]-hydroxy- | ||||||
3 | [5a]-androstan-3-one), | ||||||
4 | (xxx) methandienone (17[alpha]-methyl-17[beta]- | ||||||
5 | hydroxyandrost-1,4-dien-3-one), | ||||||
6 | (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- | ||||||
7 | dihydroxyandrost-5-ene), | ||||||
8 | (xxxii) methenolone (1-methyl-17[beta]-hydroxy- | ||||||
9 | 5[alpha]-androst-1-en-3-one), | ||||||
10 | (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- | ||||||
11 | dihydroxy-5a-androstane), | ||||||
12 | (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy | ||||||
13 | -5a-androstane), | ||||||
14 | (xxxv) 17[alpha]-methyl-3[beta],17[beta]- | ||||||
15 | dihydroxyandrost-4-ene), | ||||||
16 | (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- | ||||||
17 | methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), | ||||||
18 | (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- | ||||||
19 | hydroxyestra-4,9(10)-dien-3-one), | ||||||
20 | (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- | ||||||
21 | hydroxyestra-4,9-11-trien-3-one), | ||||||
22 | (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- | ||||||
23 | hydroxyandrost-4-en-3-one), | ||||||
24 | (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- | ||||||
25 | hydroxyestr-4-en-3-one), | ||||||
26 | (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone |
| |||||||
| |||||||
1 | (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- | ||||||
2 | androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- | ||||||
3 | 1-testosterone'), | ||||||
4 | (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), | ||||||
5 | (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- | ||||||
6 | dihydroxyestr-4-ene), | ||||||
7 | (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- | ||||||
8 | dihydroxyestr-4-ene), | ||||||
9 | (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- | ||||||
10 | dihydroxyestr-5-ene), | ||||||
11 | (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- | ||||||
12 | dihydroxyestr-5-ene), | ||||||
13 | (xlvii) 19-nor-4,9(10)-androstadienedione | ||||||
14 | (estra-4,9(10)-diene-3,17-dione), | ||||||
15 | (xlviii) 19-nor-4-androstenedione (estr-4- | ||||||
16 | en-3,17-dione), | ||||||
17 | (xlix) 19-nor-5-androstenedione (estr-5- | ||||||
18 | en-3,17-dione), | ||||||
19 | (l) norbolethone (13[beta], 17a-diethyl-17[beta]- | ||||||
20 | hydroxygon-4-en-3-one), | ||||||
21 | (li) norclostebol (4-chloro-17[beta]- | ||||||
22 | hydroxyestr-4-en-3-one), | ||||||
23 | (lii) norethandrolone (17[alpha]-ethyl-17[beta]- | ||||||
24 | hydroxyestr-4-en-3-one), | ||||||
25 | (liii) normethandrolone (17[alpha]-methyl-17[beta]- | ||||||
26 | hydroxyestr-4-en-3-one), |
| |||||||
| |||||||
1 | (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- | ||||||
2 | 2-oxa-5[alpha]-androstan-3-one), | ||||||
3 | (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- | ||||||
4 | dihydroxyandrost-4-en-3-one), | ||||||
5 | (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- | ||||||
6 | 17[beta]-hydroxy-(5[alpha]-androstan-3-one), | ||||||
7 | (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- | ||||||
8 | (5[alpha]-androst-2-eno[3,2-c]-pyrazole), | ||||||
9 | (lviii) stenbolone (17[beta]-hydroxy-2-methyl- | ||||||
10 | (5[alpha]-androst-1-en-3-one), | ||||||
11 | (lix) testolactone (13-hydroxy-3-oxo-13,17- | ||||||
12 | secoandrosta-1,4-dien-17-oic | ||||||
13 | acid lactone), | ||||||
14 | (lx) testosterone (17[beta]-hydroxyandrost- | ||||||
15 | 4-en-3-one), | ||||||
16 | (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- | ||||||
17 | diethyl-17[beta]-hydroxygon- | ||||||
18 | 4,9,11-trien-3-one), | ||||||
19 | (lxii) trenbolone (17[beta]-hydroxyestr-4,9, | ||||||
20 | 11-trien-3-one).
| ||||||
21 | Any person who is otherwise lawfully in possession of an | ||||||
22 | anabolic
steroid, or who otherwise lawfully manufactures, | ||||||
23 | distributes, dispenses,
delivers, or possesses with intent to | ||||||
24 | deliver an anabolic steroid, which
anabolic steroid is | ||||||
25 | expressly intended for and lawfully allowed to be
administered | ||||||
26 | through implants to livestock or other nonhuman species, and
|
| |||||||
| |||||||
1 | which is approved by the Secretary of Health and Human Services | ||||||
2 | for such
administration, and which the person intends to | ||||||
3 | administer or have
administered through such implants, shall | ||||||
4 | not be considered to be in
unauthorized possession or to | ||||||
5 | unlawfully manufacture, distribute, dispense,
deliver, or | ||||||
6 | possess with intent to deliver such anabolic steroid for
| ||||||
7 | purposes of this Act.
| ||||||
8 | (d) "Administration" means the Drug Enforcement | ||||||
9 | Administration,
United States Department of Justice, or its | ||||||
10 | successor agency.
| ||||||
11 | (d-5) "Clinical Director, Prescription Monitoring Program" | ||||||
12 | means a Department of Human Services administrative employee | ||||||
13 | licensed to either prescribe or dispense controlled substances | ||||||
14 | who shall run the clinical aspects of the Department of Human | ||||||
15 | Services Prescription Monitoring Program and its Prescription | ||||||
16 | Information Library. | ||||||
17 | (d-10) "Compounding" means the preparation and mixing of | ||||||
18 | components, excluding flavorings, (1) as the result of a | ||||||
19 | prescriber's prescription drug order or initiative based on the | ||||||
20 | prescriber-patient-pharmacist relationship in the course of | ||||||
21 | professional practice or (2) for the purpose of, or incident | ||||||
22 | to, research, teaching, or chemical analysis and not for sale | ||||||
23 | or dispensing. "Compounding" includes the preparation of drugs | ||||||
24 | or devices in anticipation of receiving prescription drug | ||||||
25 | orders based on routine, regularly observed dispensing | ||||||
26 | patterns. Commercially available products may be compounded |
| |||||||
| |||||||
1 | for dispensing to individual patients only if both of the | ||||||
2 | following conditions are met: (i) the commercial product is not | ||||||
3 | reasonably available from normal distribution channels in a | ||||||
4 | timely manner to meet the patient's needs and (ii) the | ||||||
5 | prescribing practitioner has requested that the drug be | ||||||
6 | compounded. | ||||||
7 | (e) "Control" means to add a drug or other substance, or | ||||||
8 | immediate
precursor, to a Schedule whether by
transfer from | ||||||
9 | another Schedule or otherwise.
| ||||||
10 | (f) "Controlled Substance" means (i) a drug, substance, or | ||||||
11 | immediate
precursor in the Schedules of Article II of this Act | ||||||
12 | or (ii) a drug or other substance, or immediate precursor, | ||||||
13 | designated as a controlled substance by the Department through | ||||||
14 | administrative rule. The term does not include distilled | ||||||
15 | spirits, wine, malt beverages, or tobacco, as those terms are
| ||||||
16 | defined or used in the Liquor Control Act and the Tobacco | ||||||
17 | Products Tax
Act.
| ||||||
18 | (f-5) "Controlled substance analog" means a substance: | ||||||
19 | (1) the chemical structure of which is substantially | ||||||
20 | similar to the chemical structure of a controlled substance | ||||||
21 | in Schedule I or II; | ||||||
22 | (2) which has a stimulant, depressant, or | ||||||
23 | hallucinogenic effect on the central nervous system that is | ||||||
24 | substantially similar to or greater than the stimulant, | ||||||
25 | depressant, or hallucinogenic effect on the central | ||||||
26 | nervous system of a controlled substance in Schedule I or |
| |||||||
| |||||||
1 | II; or | ||||||
2 | (3) with respect to a particular person, which such | ||||||
3 | person represents or intends to have a stimulant, | ||||||
4 | depressant, or hallucinogenic effect on the central | ||||||
5 | nervous system that is substantially similar to or greater | ||||||
6 | than the stimulant, depressant, or hallucinogenic effect | ||||||
7 | on the central nervous system of a controlled substance in | ||||||
8 | Schedule I or II. | ||||||
9 | (g) "Counterfeit substance" means a controlled substance, | ||||||
10 | which, or
the container or labeling of which, without | ||||||
11 | authorization bears the
trademark, trade name, or other | ||||||
12 | identifying mark, imprint, number or
device, or any likeness | ||||||
13 | thereof, of a manufacturer, distributor, or
dispenser other | ||||||
14 | than the person who in fact manufactured, distributed,
or | ||||||
15 | dispensed the substance.
| ||||||
16 | (h) "Deliver" or "delivery" means the actual, constructive | ||||||
17 | or
attempted transfer of possession of a controlled substance, | ||||||
18 | with or
without consideration, whether or not there is an | ||||||
19 | agency relationship.
| ||||||
20 | (i) "Department" means the Illinois Department of Human | ||||||
21 | Services (as
successor to the Department of Alcoholism and | ||||||
22 | Substance Abuse) or its successor agency.
| ||||||
23 | (j) (Blank).
| ||||||
24 | (k) "Department of Corrections" means the Department of | ||||||
25 | Corrections
of the State of Illinois or its successor agency.
| ||||||
26 | (l) "Department of Financial and Professional Regulation" |
| |||||||
| |||||||
1 | means the Department
of Financial and Professional Regulation | ||||||
2 | of the State of Illinois or its successor agency.
| ||||||
3 | (m) "Depressant" means any drug that (i) causes an overall | ||||||
4 | depression of central nervous system functions, (ii) causes | ||||||
5 | impaired consciousness and awareness, and (iii) can be | ||||||
6 | habit-forming or lead to a substance abuse problem, including | ||||||
7 | but not limited to alcohol, cannabis and its active principles | ||||||
8 | and their analogs, benzodiazepines and their analogs, | ||||||
9 | barbiturates and their analogs, opioids (natural and | ||||||
10 | synthetic) and their analogs, and chloral hydrate and similar | ||||||
11 | sedative hypnotics.
| ||||||
12 | (n) (Blank).
| ||||||
13 | (o) "Director" means the Director of the Illinois State | ||||||
14 | Police or his or her designated agents.
| ||||||
15 | (p) "Dispense" means to deliver a controlled substance to | ||||||
16 | an
ultimate user or research subject by or pursuant to the | ||||||
17 | lawful order of
a prescriber, including the prescribing, | ||||||
18 | administering, packaging,
labeling, or compounding necessary | ||||||
19 | to prepare the substance for that
delivery.
| ||||||
20 | (q) "Dispenser" means a practitioner who dispenses.
| ||||||
21 | (r) "Distribute" means to deliver, other than by | ||||||
22 | administering or
dispensing, a controlled substance.
| ||||||
23 | (s) "Distributor" means a person who distributes.
| ||||||
24 | (t) "Drug" means (1) substances recognized as drugs in the | ||||||
25 | official
United States Pharmacopoeia, Official Homeopathic | ||||||
26 | Pharmacopoeia of the
United States, or official National |
| |||||||
| |||||||
1 | Formulary, or any supplement to any
of them; (2) substances | ||||||
2 | intended for use in diagnosis, cure, mitigation,
treatment, or | ||||||
3 | prevention of disease in man or animals; (3) substances
(other | ||||||
4 | than food) intended to affect the structure of any function of
| ||||||
5 | the body of man or animals and (4) substances intended for use | ||||||
6 | as a
component of any article specified in clause (1), (2), or | ||||||
7 | (3) of this
subsection. It does not include devices or their | ||||||
8 | components, parts, or
accessories.
| ||||||
9 | (t-3) "Electronic health record" or "EHR" means a | ||||||
10 | systematic collection of electronic health information about | ||||||
11 | individual patients. The EHR is a digital format that is | ||||||
12 | capable of being shared across different health care settings. | ||||||
13 | (t-5) "Euthanasia agency" means
an entity certified by the | ||||||
14 | Department of Financial and Professional Regulation for the
| ||||||
15 | purpose of animal euthanasia that holds an animal control | ||||||
16 | facility license or
animal
shelter license under the Animal | ||||||
17 | Welfare Act. A euthanasia agency is
authorized to purchase, | ||||||
18 | store, possess, and utilize Schedule II nonnarcotic and
| ||||||
19 | Schedule III nonnarcotic drugs for the sole purpose of animal | ||||||
20 | euthanasia.
| ||||||
21 | (t-10) "Euthanasia drugs" means Schedule II or Schedule III | ||||||
22 | substances
(nonnarcotic controlled substances) that are used | ||||||
23 | by a euthanasia agency for
the purpose of animal euthanasia.
| ||||||
24 | (u) "Good faith" means the prescribing or dispensing of a | ||||||
25 | controlled
substance by a practitioner in the regular course of | ||||||
26 | professional
treatment to or for any person who is under his or |
| |||||||
| |||||||
1 | her treatment for a
pathology or condition other than that | ||||||
2 | individual's physical or
psychological dependence upon or | ||||||
3 | addiction to a controlled substance,
except as provided herein: | ||||||
4 | and application of the term to a pharmacist
shall mean the | ||||||
5 | dispensing of a controlled substance pursuant to the
| ||||||
6 | prescriber's order which in the professional judgment of the | ||||||
7 | pharmacist
is lawful. The pharmacist shall be guided by | ||||||
8 | accepted professional
standards including, but not limited to | ||||||
9 | the following, in making the
judgment:
| ||||||
10 | (1) lack of consistency of prescriber-patient | ||||||
11 | relationship,
| ||||||
12 | (2) frequency of prescriptions for same drug by one | ||||||
13 | prescriber for
large numbers of patients,
| ||||||
14 | (3) quantities beyond those normally prescribed,
| ||||||
15 | (4) unusual dosages (recognizing that there may be | ||||||
16 | clinical circumstances where more or less than the usual | ||||||
17 | dose may be used legitimately),
| ||||||
18 | (5) unusual geographic distances between patient, | ||||||
19 | pharmacist and
prescriber,
| ||||||
20 | (6) consistent prescribing of habit-forming drugs.
| ||||||
21 | (u-0.5) "Hallucinogen" means a drug that causes markedly | ||||||
22 | altered sensory perception leading to hallucinations of any | ||||||
23 | type. | ||||||
24 | (u-1) "Home infusion services" means services provided by a | ||||||
25 | pharmacy in
compounding solutions for direct administration to | ||||||
26 | a patient in a private
residence, long-term care facility, or |
| |||||||
| |||||||
1 | hospice setting by means of parenteral,
intravenous, | ||||||
2 | intramuscular, subcutaneous, or intraspinal infusion.
| ||||||
3 | (u-5) "Illinois State Police" means the State
Police of the | ||||||
4 | State of Illinois, or its successor agency. | ||||||
5 | (v) "Immediate precursor" means a substance:
| ||||||
6 | (1) which the Department has found to be and by rule | ||||||
7 | designated as
being a principal compound used, or produced | ||||||
8 | primarily for use, in the
manufacture of a controlled | ||||||
9 | substance;
| ||||||
10 | (2) which is an immediate chemical intermediary used or | ||||||
11 | likely to
be used in the manufacture of such controlled | ||||||
12 | substance; and
| ||||||
13 | (3) the control of which is necessary to prevent, | ||||||
14 | curtail or limit
the manufacture of such controlled | ||||||
15 | substance.
| ||||||
16 | (w) "Instructional activities" means the acts of teaching, | ||||||
17 | educating
or instructing by practitioners using controlled | ||||||
18 | substances within
educational facilities approved by the State | ||||||
19 | Board of Education or
its successor agency.
| ||||||
20 | (x) "Local authorities" means a duly organized State, | ||||||
21 | County or
Municipal peace unit or police force.
| ||||||
22 | (y) "Look-alike substance" means a substance, other than a | ||||||
23 | controlled
substance which (1) by overall dosage unit | ||||||
24 | appearance, including shape,
color, size, markings or lack | ||||||
25 | thereof, taste, consistency, or any other
identifying physical | ||||||
26 | characteristic of the substance, would lead a reasonable
person |
| |||||||
| |||||||
1 | to believe that the substance is a controlled substance, or (2) | ||||||
2 | is
expressly or impliedly represented to be a controlled | ||||||
3 | substance or is
distributed under circumstances which would | ||||||
4 | lead a reasonable person to
believe that the substance is a | ||||||
5 | controlled substance. For the purpose of
determining whether | ||||||
6 | the representations made or the circumstances of the
| ||||||
7 | distribution would lead a reasonable person to believe the | ||||||
8 | substance to be
a controlled substance under this clause (2) of | ||||||
9 | subsection (y), the court or
other authority may consider the | ||||||
10 | following factors in addition to any other
factor that may be | ||||||
11 | relevant:
| ||||||
12 | (a) statements made by the owner or person in control | ||||||
13 | of the substance
concerning its nature, use or effect;
| ||||||
14 | (b) statements made to the buyer or recipient that the | ||||||
15 | substance may
be resold for profit;
| ||||||
16 | (c) whether the substance is packaged in a manner | ||||||
17 | normally used for the
illegal distribution of controlled | ||||||
18 | substances;
| ||||||
19 | (d) whether the distribution or attempted distribution | ||||||
20 | included an
exchange of or demand for money or other | ||||||
21 | property as consideration, and
whether the amount of the | ||||||
22 | consideration was substantially greater than the
| ||||||
23 | reasonable retail market value of the substance.
| ||||||
24 | Clause (1) of this subsection (y) shall not apply to a | ||||||
25 | noncontrolled
substance in its finished dosage form that was | ||||||
26 | initially introduced into
commerce prior to the initial |
| |||||||
| |||||||
1 | introduction into commerce of a controlled
substance in its | ||||||
2 | finished dosage form which it may substantially resemble.
| ||||||
3 | Nothing in this subsection (y) prohibits the dispensing or | ||||||
4 | distributing
of noncontrolled substances by persons authorized | ||||||
5 | to dispense and
distribute controlled substances under this | ||||||
6 | Act, provided that such action
would be deemed to be carried | ||||||
7 | out in good faith under subsection (u) if the
substances | ||||||
8 | involved were controlled substances.
| ||||||
9 | Nothing in this subsection (y) or in this Act prohibits the | ||||||
10 | manufacture,
preparation, propagation, compounding, | ||||||
11 | processing, packaging, advertising
or distribution of a drug or | ||||||
12 | drugs by any person registered pursuant to
Section 510 of the | ||||||
13 | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
| ||||||
14 | (y-1) "Mail-order pharmacy" means a pharmacy that is | ||||||
15 | located in a state
of the United States that delivers, | ||||||
16 | dispenses or
distributes, through the United States Postal | ||||||
17 | Service or other common
carrier, to Illinois residents, any | ||||||
18 | substance which requires a prescription.
| ||||||
19 | (z) "Manufacture" means the production, preparation, | ||||||
20 | propagation,
compounding, conversion or processing of a | ||||||
21 | controlled substance other than methamphetamine, either
| ||||||
22 | directly or indirectly, by extraction from substances of | ||||||
23 | natural origin,
or independently by means of chemical | ||||||
24 | synthesis, or by a combination of
extraction and chemical | ||||||
25 | synthesis, and includes any packaging or
repackaging of the | ||||||
26 | substance or labeling of its container, except that
this term |
| |||||||
| |||||||
1 | does not include:
| ||||||
2 | (1) by an ultimate user, the preparation or compounding | ||||||
3 | of a
controlled substance for his or her own use; or
| ||||||
4 | (2) by a practitioner, or his or her authorized agent | ||||||
5 | under his or her
supervision, the preparation, | ||||||
6 | compounding, packaging, or labeling of a
controlled | ||||||
7 | substance:
| ||||||
8 | (a) as an incident to his or her administering or | ||||||
9 | dispensing of a
controlled substance in the course of | ||||||
10 | his or her professional practice; or
| ||||||
11 | (b) as an incident to lawful research, teaching or | ||||||
12 | chemical
analysis and not for sale.
| ||||||
13 | (z-1) (Blank).
| ||||||
14 | (z-5) "Medication shopping" means the conduct prohibited | ||||||
15 | under subsection (a) of Section 314.5 of this Act. | ||||||
16 | (z-10) "Mid-level practitioner" means (i) a physician | ||||||
17 | assistant who has been delegated authority to prescribe through | ||||||
18 | a written delegation of authority by a physician licensed to | ||||||
19 | practice medicine in all of its branches, in accordance with | ||||||
20 | Section 7.5 of the Physician Assistant Practice Act of 1987, | ||||||
21 | (ii) an advanced practice nurse who has been delegated | ||||||
22 | authority to prescribe through a written delegation of | ||||||
23 | authority by a physician licensed to practice medicine in all | ||||||
24 | of its branches or by a podiatrist, in accordance with Section | ||||||
25 | 65-40 of the Nurse Practice Act, or (iii) an animal euthanasia | ||||||
26 | agency. |
| |||||||
| |||||||
1 | (aa) "Narcotic drug" means any of the following, whether | ||||||
2 | produced
directly or indirectly by extraction from substances | ||||||
3 | of vegetable origin,
or independently by means of chemical | ||||||
4 | synthesis, or by a combination of
extraction and chemical | ||||||
5 | synthesis:
| ||||||
6 | (1) opium, opiates, derivatives of opium and opiates, | ||||||
7 | including their isomers, esters, ethers, salts, and salts | ||||||
8 | of isomers, esters, and ethers, whenever the existence of | ||||||
9 | such isomers, esters, ethers, and salts is possible within | ||||||
10 | the specific chemical designation; however the term | ||||||
11 | "narcotic drug" does not include the isoquinoline | ||||||
12 | alkaloids of opium;
| ||||||
13 | (2) (blank);
| ||||||
14 | (3) opium poppy and poppy straw;
| ||||||
15 | (4) coca leaves, except coca leaves and extracts of | ||||||
16 | coca leaves from which substantially all of the cocaine and | ||||||
17 | ecgonine, and their isomers, derivatives and salts, have | ||||||
18 | been removed;
| ||||||
19 | (5) cocaine, its salts, optical and geometric isomers, | ||||||
20 | and salts of isomers; | ||||||
21 | (6) ecgonine, its derivatives, their salts, isomers, | ||||||
22 | and salts of isomers; | ||||||
23 | (7) any compound, mixture, or preparation which | ||||||
24 | contains any quantity of any of the substances referred to | ||||||
25 | in subparagraphs (1) through (6). | ||||||
26 | (bb) "Nurse" means a registered nurse licensed under the
|
| |||||||
| |||||||
1 | Nurse Practice Act.
| ||||||
2 | (cc) (Blank).
| ||||||
3 | (dd) "Opiate" means any substance having an addiction | ||||||
4 | forming or
addiction sustaining liability similar to morphine | ||||||
5 | or being capable of
conversion into a drug having addiction | ||||||
6 | forming or addiction sustaining
liability.
| ||||||
7 | (ee) "Opium poppy" means the plant of the species Papaver
| ||||||
8 | somniferum L., except its seeds.
| ||||||
9 | (ee-5) "Oral dosage" means a tablet, capsule, elixir, or | ||||||
10 | solution or other liquid form of medication intended for | ||||||
11 | administration by mouth, but the term does not include a form | ||||||
12 | of medication intended for buccal, sublingual, or transmucosal | ||||||
13 | administration. | ||||||
14 | (ff) "Parole and Pardon Board" means the Parole and Pardon | ||||||
15 | Board of
the State of Illinois or its successor agency.
| ||||||
16 | (gg) "Person" means any individual, corporation, | ||||||
17 | mail-order pharmacy,
government or governmental subdivision or | ||||||
18 | agency, business trust, estate,
trust, partnership or | ||||||
19 | association, or any other entity.
| ||||||
20 | (hh) "Pharmacist" means any person who holds a license or | ||||||
21 | certificate of
registration as a registered pharmacist, a local | ||||||
22 | registered pharmacist
or a registered assistant pharmacist | ||||||
23 | under the Pharmacy Practice Act.
| ||||||
24 | (ii) "Pharmacy" means any store, ship or other place in | ||||||
25 | which
pharmacy is authorized to be practiced under the Pharmacy | ||||||
26 | Practice Act.
|
| |||||||
| |||||||
1 | (ii-5) "Pharmacy shopping" means the conduct prohibited | ||||||
2 | under subsection (b) of Section 314.5 of this Act. | ||||||
3 | (ii-10) "Physician" (except when the context otherwise | ||||||
4 | requires) means a person licensed to practice medicine in all | ||||||
5 | of its branches. | ||||||
6 | (jj) "Poppy straw" means all parts, except the seeds, of | ||||||
7 | the opium
poppy, after mowing.
| ||||||
8 | (kk) "Practitioner" means a physician licensed to practice | ||||||
9 | medicine in all
its branches, dentist, optometrist, | ||||||
10 | podiatrist,
veterinarian, scientific investigator, pharmacist, | ||||||
11 | physician assistant,
advanced practice nurse,
licensed | ||||||
12 | practical
nurse, registered nurse, hospital, laboratory, or | ||||||
13 | pharmacy, or other
person licensed, registered, or otherwise | ||||||
14 | lawfully permitted by the
United States or this State to | ||||||
15 | distribute, dispense, conduct research
with respect to, | ||||||
16 | administer or use in teaching or chemical analysis, a
| ||||||
17 | controlled substance in the course of professional practice or | ||||||
18 | research.
| ||||||
19 | (ll) "Pre-printed prescription" means a written | ||||||
20 | prescription upon which
the designated drug has been indicated | ||||||
21 | prior to the time of issuance; the term does not mean a written | ||||||
22 | prescription that is individually generated by machine or | ||||||
23 | computer in the prescriber's office.
| ||||||
24 | (mm) "Prescriber" means a physician licensed to practice | ||||||
25 | medicine in all
its branches, dentist, optometrist, podiatrist | ||||||
26 | or
veterinarian who issues a prescription, a physician |
| |||||||
| |||||||
1 | assistant who
issues a
prescription for a controlled substance
| ||||||
2 | in accordance
with Section 303.05, a written delegation, and a | ||||||
3 | written supervision agreement required under Section 7.5
of the
| ||||||
4 | Physician Assistant Practice Act of 1987, or an advanced | ||||||
5 | practice
nurse with prescriptive authority delegated under | ||||||
6 | Section 65-40 of the Nurse Practice Act and in accordance with | ||||||
7 | Section 303.05, a written delegation,
and a written
| ||||||
8 | collaborative agreement under Section 65-35 of the Nurse | ||||||
9 | Practice Act.
| ||||||
10 | (nn) "Prescription" means a written, facsimile, or oral | ||||||
11 | order, or an electronic order that complies with applicable | ||||||
12 | federal requirements,
of
a physician licensed to practice | ||||||
13 | medicine in all its branches,
dentist, podiatrist or | ||||||
14 | veterinarian for any controlled
substance, of an optometrist | ||||||
15 | for a Schedule III, IV, or V controlled substance in accordance | ||||||
16 | with Section 15.1 of the Illinois Optometric Practice Act of | ||||||
17 | 1987, of a physician assistant for a
controlled substance
in | ||||||
18 | accordance with Section 303.05, a written delegation, and a | ||||||
19 | written supervision agreement required under
Section 7.5 of the
| ||||||
20 | Physician Assistant Practice Act of 1987, or of an advanced | ||||||
21 | practice
nurse with prescriptive authority delegated under | ||||||
22 | Section 65-40 of the Nurse Practice Act who issues a | ||||||
23 | prescription for a
controlled substance in accordance
with
| ||||||
24 | Section 303.05, a written delegation, and a written | ||||||
25 | collaborative agreement under Section 65-35 of the Nurse | ||||||
26 | Practice Act when required by law.
|
| |||||||
| |||||||
1 | (nn-5) "Prescription Information Library" (PIL) means an | ||||||
2 | electronic library that contains reported controlled substance | ||||||
3 | data. | ||||||
4 | (nn-10) "Prescription Monitoring Program" (PMP) means the | ||||||
5 | entity that collects, tracks, and stores reported data on | ||||||
6 | controlled substances and select drugs pursuant to Section 316. | ||||||
7 | (nn-11) "Prescription Monitoring Program Advisory | ||||||
8 | Committee" (PMPAC) means a committee of voting members | ||||||
9 | consisting of licensed healthcare providers representing all | ||||||
10 | professions who are licensed to prescribe or dispense | ||||||
11 | controlled substances. The Chairperson of the PMPAC may appoint | ||||||
12 | non-licensed persons who are associated with professional | ||||||
13 | organizations representing licensed healthcare providers. | ||||||
14 | Non-licensed members shall serve as non-voting members. A | ||||||
15 | majority of the PMPAC shall be licensed health care providers | ||||||
16 | who are licensed to prescribe controlled substances. The | ||||||
17 | Committee shall serve in a consultant context regarding | ||||||
18 | longitudinal evaluations of compliance with evidence based | ||||||
19 | clinical practice and the prescribing of controlled | ||||||
20 | substances. The Committee shall make recommendations regarding | ||||||
21 | scheduling of controlled substances and recommendations | ||||||
22 | concerning continuing education designed at improving the | ||||||
23 | health and safety of the citizens of Illinois regarding | ||||||
24 | pharmacotherapies of controlled substances. | ||||||
25 | (oo) "Production" or "produce" means manufacture, | ||||||
26 | planting,
cultivating, growing, or harvesting of a controlled |
| |||||||
| |||||||
1 | substance other than methamphetamine.
| ||||||
2 | (pp) "Registrant" means every person who is required to | ||||||
3 | register
under Section 302 of this Act.
| ||||||
4 | (qq) "Registry number" means the number assigned to each | ||||||
5 | person
authorized to handle controlled substances under the | ||||||
6 | laws of the United
States and of this State.
| ||||||
7 | (qq-5) "Secretary" means, as the context requires, either | ||||||
8 | the Secretary of the Department or the Secretary of the | ||||||
9 | Department of Financial and Professional Regulation, and the | ||||||
10 | Secretary's designated agents. | ||||||
11 | (rr) "State" includes the State of Illinois and any state, | ||||||
12 | district,
commonwealth, territory, insular possession thereof, | ||||||
13 | and any area
subject to the legal authority of the United | ||||||
14 | States of America.
| ||||||
15 | (rr-5) "Stimulant" means any drug that (i) causes an | ||||||
16 | overall excitation of central nervous system functions, (ii) | ||||||
17 | causes impaired consciousness and awareness, and (iii) can be | ||||||
18 | habit-forming or lead to a substance abuse problem, including | ||||||
19 | but not limited to amphetamines and their analogs, | ||||||
20 | methylphenidate and its analogs, cocaine, and phencyclidine | ||||||
21 | and its analogs. | ||||||
22 | (ss) "Ultimate user" means a person who lawfully possesses | ||||||
23 | a
controlled substance for his or her own use or for the use of | ||||||
24 | a member of his or her
household or for administering to an | ||||||
25 | animal owned by him or her or by a member
of his or her | ||||||
26 | household.
|
| |||||||
| |||||||
1 | (Source: P.A. 96-189, eff. 8-10-09; 96-268, eff. 8-11-09; | ||||||
2 | 97-334, eff. 1-1-12 .)
| ||||||
3 | (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
| ||||||
4 | Sec. 206. (a) The controlled substances listed in this | ||||||
5 | Section are
included in Schedule II.
| ||||||
6 | (b) Unless specifically excepted or unless listed in | ||||||
7 | another
schedule, any of the following substances whether | ||||||
8 | produced directly or
indirectly by extraction from substances | ||||||
9 | of vegetable origin, or
independently by means of chemical | ||||||
10 | synthesis, or by combination of
extraction and chemical | ||||||
11 | synthesis:
| ||||||
12 | (1) Opium and opiates, and any salt, compound, | ||||||
13 | derivative or
preparation of opium or opiate, excluding | ||||||
14 | apomorphine, dextrorphan,
levopropoxyphene,
nalbuphine, | ||||||
15 | nalmefene, naloxone, and naltrexone, and their respective
| ||||||
16 | salts, but including the following:
| ||||||
17 | (i) Raw Opium;
| ||||||
18 | (ii) Opium extracts;
| ||||||
19 | (iii) Opium fluid extracts;
| ||||||
20 | (iv) Powdered opium;
| ||||||
21 | (v) Granulated opium;
| ||||||
22 | (vi) Tincture of opium;
| ||||||
23 | (vii) Codeine;
| ||||||
24 | (viii) Ethylmorphine;
| ||||||
25 | (ix) Etorphine Hydrochloride;
|
| |||||||
| |||||||
1 | (x) Hydrocodone;
| ||||||
2 | (xi) Hydromorphone;
| ||||||
3 | (xii) Metopon;
| ||||||
4 | (xiii) Morphine;
| ||||||
5 | (xiv) Oxycodone;
| ||||||
6 | (xv) Oxymorphone;
| ||||||
7 | (xv.5) Tapentadol;
| ||||||
8 | (xvi) Thebaine;
| ||||||
9 | (xvii) Thebaine-derived butorphanol.
| ||||||
10 | (xviii) Dextromethorphan, except drug products | ||||||
11 | that may be dispensed pursuant to a prescription order | ||||||
12 | of a practitioner and are sold in compliance with the | ||||||
13 | safety and labeling standards as set forth by the | ||||||
14 | United States Food and Drug Administration, or drug | ||||||
15 | products containing dextromethorphan that are sold in | ||||||
16 | solid, tablet, liquid, capsule, powder, thin film, or | ||||||
17 | gel form and which are formulated, packaged, and sold | ||||||
18 | in dosages and concentrations for use as an | ||||||
19 | over-the-counter drug product. For the purposes of | ||||||
20 | this Section, "over-the-counter drug product" means a | ||||||
21 | drug that is available to consumers without a | ||||||
22 | prescription and sold in compliance with the safety and | ||||||
23 | labeling standards as set forth by the United States | ||||||
24 | Food and Drug Administration.
| ||||||
25 | (2) Any salt, compound, isomer, derivative or | ||||||
26 | preparation thereof
which is chemically equivalent or |
| |||||||
| |||||||
1 | identical with any of the substances
referred to in | ||||||
2 | subparagraph (1), but not including the isoquinoline
| ||||||
3 | alkaloids of opium;
| ||||||
4 | (3) Opium poppy and poppy straw;
| ||||||
5 | (4) Coca leaves and any salt, compound, isomer, salt of | ||||||
6 | an isomer,
derivative, or preparation of coca leaves | ||||||
7 | including cocaine or ecgonine,
and any salt, compound, | ||||||
8 | isomer, derivative, or preparation thereof which is
| ||||||
9 | chemically equivalent or identical with any of these | ||||||
10 | substances, but not
including decocainized coca leaves or | ||||||
11 | extractions of coca leaves which do
not contain cocaine or | ||||||
12 | ecgonine (for the purpose of this paragraph, the
term | ||||||
13 | "isomer" includes optical, positional and geometric | ||||||
14 | isomers);
| ||||||
15 | (5) Concentrate of poppy straw (the crude extract of | ||||||
16 | poppy straw in
either liquid, solid or powder form which | ||||||
17 | contains the phenanthrine
alkaloids of the opium poppy).
| ||||||
18 | (c) Unless specifically excepted or unless listed in | ||||||
19 | another
schedule any of the following opiates, including their | ||||||
20 | isomers, esters,
ethers, salts, and salts of isomers, whenever | ||||||
21 | the existence of these
isomers, esters, ethers and salts is | ||||||
22 | possible within the specific
chemical designation, dextrorphan | ||||||
23 | excepted:
| ||||||
24 | (1) Alfentanil;
| ||||||
25 | (1.1) Carfentanil;
| ||||||
26 | (2) Alphaprodine;
|
| |||||||
| |||||||
1 | (3) Anileridine;
| ||||||
2 | (4) Bezitramide;
| ||||||
3 | (5) Bulk Dextropropoxyphene (non-dosage forms);
| ||||||
4 | (6) Dihydrocodeine;
| ||||||
5 | (6.5) Dihydrocodeinone (Hydrocodone), with one or more | ||||||
6 | active, non-narcotic ingredients in regional therapeutic | ||||||
7 | amounts;
| ||||||
8 | (7) Diphenoxylate;
| ||||||
9 | (8) Fentanyl;
| ||||||
10 | (9) Sufentanil;
| ||||||
11 | (9.5) Remifentanil;
| ||||||
12 | (10) Isomethadone;
| ||||||
13 | (11) Levomethorphan;
| ||||||
14 | (12) Levorphanol (Levorphan);
| ||||||
15 | (13) Metazocine;
| ||||||
16 | (14) Methadone;
| ||||||
17 | (15) Methadone-Intermediate,
| ||||||
18 | 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
| ||||||
19 | (16) Moramide-Intermediate,
| ||||||
20 | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
| ||||||
21 | acid;
| ||||||
22 | (17) Pethidine (meperidine);
| ||||||
23 | (18) Pethidine-Intermediate-A,
| ||||||
24 | 4-cyano-1-methyl-4-phenylpiperidine;
| ||||||
25 | (19) Pethidine-Intermediate-B,
| ||||||
26 | ethyl-4-phenylpiperidine-4-carboxylate;
|
| |||||||
| |||||||
1 | (20) Pethidine-Intermediate-C,
| ||||||
2 | 1-methyl-4-phenylpiperidine-4-carboxylic acid;
| ||||||
3 | (21) Phenazocine;
| ||||||
4 | (22) Piminodine;
| ||||||
5 | (23) Racemethorphan;
| ||||||
6 | (24) Racemorphan;
| ||||||
7 | (25) Levo-alphacetylmethadol (some other names:
| ||||||
8 | levo-alpha-acetylmethadol,
levomethadyl acetate, LAAM).
| ||||||
9 | (d) Unless specifically excepted or unless listed in | ||||||
10 | another
schedule, any material, compound, mixture, or | ||||||
11 | preparation which contains
any quantity of the following | ||||||
12 | substances having a stimulant effect on
the central nervous | ||||||
13 | system:
| ||||||
14 | (1) Amphetamine, its salts, optical isomers, and salts | ||||||
15 | of its
optical isomers;
| ||||||
16 | (2) Methamphetamine, its salts, isomers, and salts of | ||||||
17 | its isomers;
| ||||||
18 | (3) Phenmetrazine and its salts;
| ||||||
19 | (4) Methylphenidate;
| ||||||
20 | (5) Lisdexamfetamine. | ||||||
21 | (e) Unless specifically excepted or unless listed in | ||||||
22 | another
schedule, any material, compound, mixture, or | ||||||
23 | preparation which contains
any quantity of the following | ||||||
24 | substances having a depressant effect on
the central nervous | ||||||
25 | system, including its salts, isomers, and salts of
isomers | ||||||
26 | whenever the existence of such salts, isomers, and salts of
|
| |||||||
| |||||||
1 | isomers is possible within the specific chemical designation:
| ||||||
2 | (1) Amobarbital;
| ||||||
3 | (2) Secobarbital;
| ||||||
4 | (3) Pentobarbital;
| ||||||
5 | (4) Pentazocine;
| ||||||
6 | (5) Phencyclidine;
| ||||||
7 | (6) Gluthethimide;
| ||||||
8 | (7) (Blank).
| ||||||
9 | (f) Unless specifically excepted or unless listed in | ||||||
10 | another schedule,
any material, compound, mixture, or | ||||||
11 | preparation which contains any quantity
of the following | ||||||
12 | substances:
| ||||||
13 | (1) Immediate precursor to amphetamine and | ||||||
14 | methamphetamine:
| ||||||
15 | (i) Phenylacetone
| ||||||
16 | Some trade or other names: phenyl-2-propanone;
| ||||||
17 | P2P; benzyl methyl ketone; methyl benzyl ketone.
| ||||||
18 | (2) Immediate precursors to phencyclidine:
| ||||||
19 | (i) 1-phenylcyclohexylamine;
| ||||||
20 | (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
| ||||||
21 | (3) Nabilone.
| ||||||
22 | (Source: P.A. 97-334, eff. 1-1-12.)
| ||||||
23 | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
| ||||||
24 | Sec. 208.
(a) The controlled substances listed in this | ||||||
25 | Section are
included in Schedule III.
|
| |||||||
| |||||||
1 | (b) Unless specifically excepted or unless listed in | ||||||
2 | another
schedule, any material, compound, mixture, or | ||||||
3 | preparation which contains
any quantity of the following | ||||||
4 | substances having a stimulant effect on
the central nervous | ||||||
5 | system, including its salts, isomers (whether
optical | ||||||
6 | position, or geometric), and salts of such isomers whenever the
| ||||||
7 | existence of such salts, isomers, and salts of isomers is | ||||||
8 | possible
within the specific chemical designation;
| ||||||
9 | (1) Those compounds, mixtures, or preparations in | ||||||
10 | dosage unit form
containing any stimulant substances | ||||||
11 | listed in Schedule II which
compounds, mixtures, or | ||||||
12 | preparations were listed on August 25, 1971, as
excepted | ||||||
13 | compounds under Title 21, Code of Federal Regulations, | ||||||
14 | Section
308.32, and any other drug of the quantitative | ||||||
15 | composition shown in that
list for those drugs or which is | ||||||
16 | the same except that it contains a
lesser quantity of | ||||||
17 | controlled substances;
| ||||||
18 | (2) Benzphetamine;
| ||||||
19 | (3) Chlorphentermine;
| ||||||
20 | (4) Clortermine;
| ||||||
21 | (5) Phendimetrazine.
| ||||||
22 | (c) Unless specifically excepted or unless listed in | ||||||
23 | another
schedule, any material, compound, mixture, or | ||||||
24 | preparation which contains
any quantity of the following | ||||||
25 | substances having a potential for abuse
associated with a | ||||||
26 | depressant effect on the central nervous system:
|
| |||||||
| |||||||
1 | (1) Any compound, mixture, or preparation containing | ||||||
2 | amobarbital,
secobarbital, pentobarbital or any salt | ||||||
3 | thereof and one or more other
active medicinal ingredients | ||||||
4 | which are not listed in any schedule;
| ||||||
5 | (2) Any suppository dosage form containing | ||||||
6 | amobarbital,
secobarbital, pentobarbital or any salt of | ||||||
7 | any of these drugs and
approved by the Federal Food and | ||||||
8 | Drug Administration for marketing only
as a suppository;
| ||||||
9 | (3) Any substance which contains any quantity of a | ||||||
10 | derivative of
barbituric acid, or any salt thereof:
| ||||||
11 | (3.1) Aprobarbital; | ||||||
12 | (3.2) Butabarbital (secbutabarbital); | ||||||
13 | (3.3) Butalbital; | ||||||
14 | (3.4) Butobarbital (butethal);
| ||||||
15 | (4) Chlorhexadol;
| ||||||
16 | (5) Methyprylon;
| ||||||
17 | (6) Sulfondiethylmethane;
| ||||||
18 | (7) Sulfonethylmethane;
| ||||||
19 | (8) Sulfonmethane;
| ||||||
20 | (9) Lysergic acid;
| ||||||
21 | (10) Lysergic acid amide;
| ||||||
22 | (10.1) Tiletamine or zolazepam or both, or any salt of | ||||||
23 | either of them.
| ||||||
24 | Some trade or other names for a tiletamine-zolazepam
| ||||||
25 | combination product: Telazol.
| ||||||
26 | Some trade or other names for Tiletamine:
|
| |||||||
| |||||||
1 | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| ||||||
2 | Some trade or other names for zolazepam:
| ||||||
3 | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| ||||||
4 | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
| ||||||
5 | (11) Any material, compound, mixture or preparation | ||||||
6 | containing not more
than 12.5 milligrams of pentazocine or | ||||||
7 | any of its salts, per 325 milligrams of
aspirin;
| ||||||
8 | (12) Any material, compound, mixture or preparation | ||||||
9 | containing not
more than 12.5 milligrams of pentazocine or | ||||||
10 | any of its salts, per 325
milligrams of acetaminophen;
| ||||||
11 | (13) Any material, compound, mixture or preparation | ||||||
12 | containing not more
than 50 milligrams of pentazocine or | ||||||
13 | any of its salts plus naloxone HCl USP
0.5 milligrams, per | ||||||
14 | dosage unit;
| ||||||
15 | (14) Ketamine;
| ||||||
16 | (15) Thiopental. | ||||||
17 | (d) Nalorphine.
| ||||||
18 | (d.5) Buprenorphine. | ||||||
19 | (e) Unless specifically excepted or unless listed in | ||||||
20 | another
schedule, any material, compound, mixture, or | ||||||
21 | preparation containing
limited quantities of any of the | ||||||
22 | following narcotic drugs, or their salts
calculated as the free | ||||||
23 | anhydrous base or alkaloid, as set forth below:
| ||||||
24 | (1) not more than 1.8 grams of codeine per 100
| ||||||
25 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
26 | with an
equal or greater quantity of an isoquinoline |
| |||||||
| |||||||
1 | alkaloid of opium;
| ||||||
2 | (2) not more than 1.8 grams of codeine per 100
| ||||||
3 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
4 | with one or
more active non-narcotic ingredients in | ||||||
5 | recognized therapeutic amounts;
| ||||||
6 | (3) (blank) not more than 300 milligrams of | ||||||
7 | dihydrocodeinone per 100 milliliters
or not more than 15 | ||||||
8 | milligrams per dosage
unit, with a fourfold or greater | ||||||
9 | quantity of an isoquinoline alkaloid of
opium ;
| ||||||
10 | (4) (blank) not more than 300 milligrams of | ||||||
11 | dihydrocodeinone per 100 milliliters
or not more than 15 | ||||||
12 | milligrams per dosage
unit, with one or more active, | ||||||
13 | non-narcotic ingredients in recognized
therapeutic | ||||||
14 | amounts ;
| ||||||
15 | (5) not more than 1.8 grams of dihydrocodeine
per 100 | ||||||
16 | milliliters or not more than 90 milligrams per dosage unit, | ||||||
17 | with
one or more active, non-narcotic ingredients in | ||||||
18 | recognized therapeutic
amounts;
| ||||||
19 | (6) not more than 300 milligrams of ethylmorphine per | ||||||
20 | 100 milliliters
or not more than 15 milligrams per dosage
| ||||||
21 | unit, with one or more active, non-narcotic ingredients in | ||||||
22 | recognized
therapeutic amounts;
| ||||||
23 | (7) not more than 500 milligrams of opium per 100 | ||||||
24 | milliliters or per
100 grams, or not more than 25 | ||||||
25 | milligrams per dosage unit, with one or
more active, | ||||||
26 | non-narcotic ingredients in recognized therapeutic |
| |||||||
| |||||||
1 | amounts;
| ||||||
2 | (8) not more than 50 milligrams of morphine
per 100 | ||||||
3 | milliliters or per 100 grams with one or more active,
| ||||||
4 | non-narcotic ingredients in recognized therapeutic | ||||||
5 | amounts.
| ||||||
6 | (f) Anabolic steroids, except the following anabolic | ||||||
7 | steroids that are
exempt:
| ||||||
8 | (1) Androgyn L.A.;
| ||||||
9 | (2) Andro-Estro 90-4;
| ||||||
10 | (3) depANDROGYN;
| ||||||
11 | (4) DEPO-T.E.;
| ||||||
12 | (5) depTESTROGEN;
| ||||||
13 | (6) Duomone;
| ||||||
14 | (7) DURATESTRIN;
| ||||||
15 | (8) DUO-SPAN II;
| ||||||
16 | (9) Estratest;
| ||||||
17 | (10) Estratest H.S.;
| ||||||
18 | (11) PAN ESTRA TEST;
| ||||||
19 | (12) Premarin with Methyltestosterone;
| ||||||
20 | (13) TEST-ESTRO Cypionates;
| ||||||
21 | (14) Testosterone Cyp 50 Estradiol Cyp 2;
| ||||||
22 | (15) Testosterone Cypionate-Estradiol Cypionate | ||||||
23 | injection; and
| ||||||
24 | (16) Testosterone Enanthate-Estradiol Valerate | ||||||
25 | injection.
| ||||||
26 | (g) Hallucinogenic
substances.
|
| |||||||
| |||||||
1 | (1) Dronabinol (synthetic) in sesame oil and | ||||||
2 | encapsulated in a soft
gelatin capsule in a U.S.
Food and | ||||||
3 | Drug Administration approved product. Some other names for
| ||||||
4 | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
| ||||||
5 | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)
pyran-1-ol) or | ||||||
6 | (-)-delta-9-(trans)-tetrahydrocannabinol.
| ||||||
7 | (2) (Reserved).
| ||||||
8 | (h) The Department may except by rule any compound, | ||||||
9 | mixture, or
preparation containing any stimulant or depressant | ||||||
10 | substance listed in
subsection (b) from the application of all | ||||||
11 | or any part of this
Act if the compound, mixture, or | ||||||
12 | preparation contains one or more active
medicinal ingredients | ||||||
13 | not having a stimulant or depressant effect on the
central | ||||||
14 | nervous system, and if the admixtures are included therein in
| ||||||
15 | combinations, quantity, proportion, or concentration that | ||||||
16 | vitiate the
potential for abuse of the substances which have a | ||||||
17 | stimulant or
depressant effect on the central nervous system.
| ||||||
18 | (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; | ||||||
19 | 97-334, eff. 1-1-12.)
| ||||||
20 | (720 ILCS 570/316)
| ||||||
21 | Sec. 316. Prescription monitoring program. | ||||||
22 | (a) The Department must provide for a
prescription | ||||||
23 | monitoring program for Schedule II, III, IV, and V controlled | ||||||
24 | substances , the purpose of which is to develop a clinical tool | ||||||
25 | to assist healthcare providers in preventing accidental |
| |||||||
| |||||||
1 | overdoses or duplications of controlled substances to the | ||||||
2 | patients they are treating. The Program shall include that | ||||||
3 | includes the following components and requirements:
| ||||||
4 | (1) The
dispenser must transmit to the
central | ||||||
5 | repository, in a form and manner specified by the | ||||||
6 | Department, the following information:
| ||||||
7 | (A) The recipient's name.
| ||||||
8 | (B) The recipient's address.
| ||||||
9 | (C) The national drug code number of the controlled
| ||||||
10 | substance
dispensed.
| ||||||
11 | (D) The date the controlled substance is | ||||||
12 | dispensed.
| ||||||
13 | (E) The quantity of the controlled substance | ||||||
14 | dispensed.
| ||||||
15 | (F) The dispenser's United States Drug Enforcement | ||||||
16 | Administration
registration number.
| ||||||
17 | (G) The prescriber's United States Drug | ||||||
18 | Enforcement Administration
registration number.
| ||||||
19 | (H) The dates the controlled substance | ||||||
20 | prescription is filled. | ||||||
21 | (I) The payment type used to purchase the | ||||||
22 | controlled substance (i.e. Medicaid, cash, third party | ||||||
23 | insurance). | ||||||
24 | (J) The patient location code (i.e. home, nursing | ||||||
25 | home, outpatient, etc.) for the controlled substances | ||||||
26 | other than those filled at a retail pharmacy. |
| |||||||
| |||||||
1 | (K) Any additional information that may be | ||||||
2 | required by the department by administrative rule, | ||||||
3 | including but not limited to information required for | ||||||
4 | compliance with the criteria for electronic reporting | ||||||
5 | of the American Society for Automation and Pharmacy or | ||||||
6 | its successor.
| ||||||
7 | (2) The information required to be transmitted under | ||||||
8 | this Section must be
transmitted not more than 7 days after | ||||||
9 | the date on which a
controlled substance is dispensed, or | ||||||
10 | at such other time as may be required by the Department by | ||||||
11 | administrative rule.
| ||||||
12 | (3) A dispenser must transmit the information required | ||||||
13 | under this Section
by:
| ||||||
14 | (A) an electronic device compatible with the | ||||||
15 | receiving device of the
central repository;
| ||||||
16 | (B) a computer diskette;
| ||||||
17 | (C) a magnetic tape; or
| ||||||
18 | (D) a pharmacy universal claim form or Pharmacy | ||||||
19 | Inventory Control form;
| ||||||
20 | (4) The Department may impose a civil fine of up to | ||||||
21 | $100 per day for willful failure to report controlled | ||||||
22 | substance dispensing to the Prescription Monitoring | ||||||
23 | Program. The fine shall be calculated on no more than the | ||||||
24 | number of days from the time the report was required to be | ||||||
25 | made until the time the problem was resolved, and shall be | ||||||
26 | payable to the Prescription Monitoring Program.
|
| |||||||
| |||||||
1 | (b) The Department, by rule, may include in the monitoring | ||||||
2 | program certain other select drugs that are not included in | ||||||
3 | Schedule II, III, IV, or V. The prescription monitoring program | ||||||
4 | does not apply to
controlled substance prescriptions as | ||||||
5 | exempted under Section
313.
| ||||||
6 | (c) The collection of data on select drugs and scheduled | ||||||
7 | substances by the Prescription Monitoring Program may be used | ||||||
8 | as a tool for addressing oversight requirements of long-term | ||||||
9 | care institutions as set forth by Public Act 96-1372. Long-term | ||||||
10 | care pharmacies shall transmit patient medication profiles to | ||||||
11 | the Prescription Monitoring Program monthly or more frequently | ||||||
12 | as established by administrative rule. | ||||||
13 | (d) By January 1, 2015, all Electronic Health Records | ||||||
14 | Systems should interface with the Prescription Monitoring | ||||||
15 | Program application program interface to insure that all | ||||||
16 | providers have access to specific patient records as they are | ||||||
17 | treating the patient. No prescriber shall be fined or otherwise | ||||||
18 | penalized if the electronic health records system he or she is | ||||||
19 | using does not effectively interface with the Prescription | ||||||
20 | Monitoring Program. | ||||||
21 | (Source: P.A. 97-334, eff. 1-1-12.)
| ||||||
22 | (720 ILCS 570/317.5 new) | ||||||
23 | Sec. 317.5. Access to the Prescription Monitoring Program | ||||||
24 | Database. | ||||||
25 | (a) All licensed prescribers of controlled substances may |
| |||||||
| |||||||
1 | register for individual access to the Prescription Monitoring | ||||||
2 | Program, where the data is to be used in treating their | ||||||
3 | patients. | ||||||
4 | (b) Those licensed prescribers who have registered to | ||||||
5 | access the Prescription Monitoring Program, may authorize a | ||||||
6 | designee to consult the Prescription Monitoring Program on | ||||||
7 | their behalf. The practitioner assumes all liability from that | ||||||
8 | authorization. The Prescription Monitoring Program Advisory | ||||||
9 | Committee shall draft rules with reasonable parameters | ||||||
10 | concerning a practitioner's authority to authorize a designee. | ||||||
11 | (c) Any Electronic Medical Records System may apply for | ||||||
12 | access to the Prescription Monitoring Program on behalf of | ||||||
13 | their enrolled practitioners. | ||||||
14 | (d) A Pharmacist-in-charge (PIC) or his or her designee | ||||||
15 | (which may be permitted by administrative rules) may register | ||||||
16 | for individual access to the Prescription Monitoring Program. | ||||||
17 | (e) Any Pharmacy Electronic Record System may apply for | ||||||
18 | access to the Prescription Monitoring Program on behalf of | ||||||
19 | their enrolled pharmacies to streamline access to patient | ||||||
20 | specific data to address provision of pharmaceutical care. | ||||||
21 | (f) Prescribers, pharmacists, or persons acting on their | ||||||
22 | behalf, in good faith, are immune from any recourse (civil or | ||||||
23 | criminal liability, or professional discipline) arising from | ||||||
24 | any false, incomplete or inaccurate information submitted to or | ||||||
25 | reported to the Prescription Monitoring Program registry.
|
| |||||||
| |||||||
1 | (720 ILCS 570/319)
| ||||||
2 | Sec. 319. Rules. The Department must adopt rules under the | ||||||
3 | Illinois
Administrative
Procedure Act to
implement Sections | ||||||
4 | 316 through 321, including the following:
| ||||||
5 | (1) Information collection and retrieval procedures | ||||||
6 | for the central
repository, including the
controlled | ||||||
7 | substances to be included in
the program
required under | ||||||
8 | Section 316 and Section 321 (now repealed).
| ||||||
9 | (2) Design for the creation of the database required | ||||||
10 | under Section
317.
| ||||||
11 | (3) Requirements for the development and installation | ||||||
12 | of on-line
electronic access by the Department to | ||||||
13 | information collected by the
central repository. | ||||||
14 | (4) The process for choosing members for the advisory | ||||||
15 | committee, the clinical consulting long term care advisory | ||||||
16 | committee, and the clinical outcomes research group under | ||||||
17 | the direction of the Prescription Monitoring Program | ||||||
18 | Clinical Director.
| ||||||
19 | (Source: P.A. 97-334, eff. 1-1-12.)
| ||||||
20 | (720 ILCS 570/320)
| ||||||
21 | Sec. 320. Advisory committee.
| ||||||
22 | (a) The Secretary of the Department of Human Services must | ||||||
23 | appoint an advisory committee to
assist the Department in | ||||||
24 | implementing the controlled substance
prescription
monitoring | ||||||
25 | program created by Section 316 and former Section 321 of this |
| |||||||
| |||||||
1 | Act.
The Advisory Committee consists of prescribers and | ||||||
2 | dispensers.
| ||||||
3 | (b) The Secretary of the Department of Human Services or | ||||||
4 | his or her designee must determine the number of members to
| ||||||
5 | serve on the advisory committee. The Chair of the Prescription | ||||||
6 | Monitoring Program Advisory Committee and the other clinical | ||||||
7 | consulting committees shall be the Prescription Monitoring | ||||||
8 | Program Clinical Director Secretary must choose one of the | ||||||
9 | members
of the advisory committee to serve as chair of the | ||||||
10 | committee .
| ||||||
11 | (c) The advisory committee may appoint its other officers | ||||||
12 | as it deems
appropriate.
| ||||||
13 | (d) The members of the advisory committee shall receive no | ||||||
14 | compensation for
their services as members of the advisory | ||||||
15 | committee but may be reimbursed for
their actual expenses | ||||||
16 | incurred in serving on the advisory committee.
| ||||||
17 | (e) The advisory committee shall: | ||||||
18 | (1) provide a uniform approach to reviewing this Act in | ||||||
19 | order to determine whether changes should be recommended to | ||||||
20 | the General Assembly. | ||||||
21 | (2) review current drug schedules in order to manage | ||||||
22 | changes to the administrative rules pertaining to the | ||||||
23 | utilization of this Act. | ||||||
24 | (Source: P.A. 97-334, eff. 1-1-12.)".
|